Drug Resistance Updates

Papers
(The H4-Index of Drug Resistance Updates is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance264
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment171
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors159
Anticancer drug resistance: An update and perspective121
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming121
The role of alternative splicing in cancer: From oncogenesis to drug resistance116
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy108
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification107
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance104
Therapeutic strategies to overcome taxane resistance in cancer101
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies99
Novel nanomedicines to overcome cancer multidrug resistance94
Hypoxia as a driver of resistance to immunotherapy93
Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs88
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance79
A review on antimicrobial botanicals, phytochemicals and natural resistance modifying agents from Apocynaceae family: Possible therapeutic approaches against multidrug resistance in pathogenic microor78
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses77
Nanomedicine to target multidrug resistant tumors71
Antimicrobial peptides for combating drug-resistant bacterial infections67
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function60
Repurposing old drugs to fight multidrug resistant cancers58
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma48
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects47
Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance45
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer44
COVID-19 update: The race to therapeutic development43
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer43
Impact of cancer metabolism on therapy resistance – Clinical implications42
The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology42
Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci42
Overcoming cancer chemotherapy resistance by the induction of ferroptosis41
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine40
Long non-coding RNA mediated drug resistance in breast cancer38
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs38
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition37
Metallothionein isoforms as double agents – Their roles in carcinogenesis, cancer progression and chemoresistance37
Cross-resistance and drug sequence in prostate cancer37
0.020375967025757